BIIB

SEC source: 0001127602-19-006080 · form4.xml · nonDerivative · entry 4

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,244

SEC source: 0001127602-19-006080 · form4.xml · nonDerivative · entry 3

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,561

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-006080 · form4.xml · nonDerivative · entry 2

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,483

SEC source: 0001127602-19-006080 · form4.xml · nonDerivative · entry 1

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,717

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-006077 · form4.xml · derivative · entry 8

Ehlers Michael D · CIK 0001674364 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,460

Underlying: Common Stock · 13,460 shares

Expires 2022-02-12

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-006077 · form4.xml · derivative · entry 7

Ehlers Michael D · CIK 0001674364 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,894

Underlying: Common Stock · 1,697 shares

Expires 2021-02-12

F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-006077 · form4.xml · derivative · entry 6

Ehlers Michael D · CIK 0001674364 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,591

Underlying: Common Stock · 2,249 shares

Expires 2021-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-006077 · form4.xml · derivative · entry 5

Ehlers Michael D · CIK 0001674364 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,157

Underlying: Common Stock · 1,578 shares

Expires 2020-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The restricted stock units will vest in 2 annual installments. One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date.

SEC source: 0001127602-19-006077 · form4.xml · nonDerivative · entry 4

Ehlers Michael D · CIK 0001674364 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,841.171

SEC source: 0001127602-19-006077 · form4.xml · nonDerivative · entry 3

Ehlers Michael D · CIK 0001674364 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,639.171

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-006077 · form4.xml · nonDerivative · entry 2

Ehlers Michael D · CIK 0001674364 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,390.171

SEC source: 0001127602-19-006077 · form4.xml · nonDerivative · entry 1

Ehlers Michael D · CIK 0001674364 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,859.171

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-006075 · form4.xml · derivative · entry 1

CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,520

Underlying: Common Stock · 12,520 shares

Expires 2022-02-12

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-006073 · form4.xml · derivative · entry 8

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,020

Underlying: Common Stock · 10,020 shares

Expires 2022-02-12

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-006073 · form4.xml · derivative · entry 7

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,742

Underlying: Common Stock · 1,448 shares

Expires 2021-02-12

F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-006073 · form4.xml · derivative · entry 6

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,190

Underlying: Common Stock · 1,920 shares

Expires 2021-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-006073 · form4.xml · derivative · entry 5

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,697

Underlying: Common Stock · 1,348 shares

Expires 2020-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The restricted stock units will vest in 2 annual installments. One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date.

SEC source: 0001127602-19-006073 · form4.xml · nonDerivative · entry 4

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,091

SEC source: 0001127602-19-006073 · form4.xml · nonDerivative · entry 3

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,710

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-006073 · form4.xml · nonDerivative · entry 2

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,790

SEC source: 0001127602-19-006073 · form4.xml · nonDerivative · entry 1

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,192

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-003363 · form4.xml · nonDerivative · entry 3

DENNER ALEXANDER J · CIK 0001361754 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 524,658

F1 · ownership.nature: Dr. Denner disclaims beneficial ownership of the shares being reported on this Form 4 except to the extent of his pecuniary interest therein.

F2 · ownership.nature: Sarissa Capital Management GP LLC, a Delaware limited liability company ("Sarissa Capital GP"), is the general partner of Sarissa Capital Management LP, a Delaware limited partnership ("Sarissa Capital"), the investment advisor to certain investment funds. Alexander Denner is the Chief Investment Officer of Sarissa Capital and the managing member of Sarissa Capital GP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that those funds directly beneficially own.

SEC source: 0001127602-19-003363 · form4.xml · nonDerivative · entry 2

DENNER ALEXANDER J · CIK 0001361754 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 517,658

F1 · ownership.nature: Dr. Denner disclaims beneficial ownership of the shares being reported on this Form 4 except to the extent of his pecuniary interest therein.

F2 · ownership.nature: Sarissa Capital Management GP LLC, a Delaware limited liability company ("Sarissa Capital GP"), is the general partner of Sarissa Capital Management LP, a Delaware limited partnership ("Sarissa Capital"), the investment advisor to certain investment funds. Alexander Denner is the Chief Investment Officer of Sarissa Capital and the managing member of Sarissa Capital GP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that those funds directly beneficially own.

SEC source: 0001127602-19-003363 · form4.xml · nonDerivative · entry 1

DENNER ALEXANDER J · CIK 0001361754 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 491,858

F1 · ownership.nature: Dr. Denner disclaims beneficial ownership of the shares being reported on this Form 4 except to the extent of his pecuniary interest therein.

F2 · ownership.nature: Sarissa Capital Management GP LLC, a Delaware limited liability company ("Sarissa Capital GP"), is the general partner of Sarissa Capital Management LP, a Delaware limited partnership ("Sarissa Capital"), the investment advisor to certain investment funds. Alexander Denner is the Chief Investment Officer of Sarissa Capital and the managing member of Sarissa Capital GP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that those funds directly beneficially own.

SEC source: 0001127602-19-001282 · form4.xml · derivative · entry 4

CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,988

Underlying: Common Stock · 1,661 shares

Expires 2021-01-02

F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-19-001282 · form4.xml · derivative · entry 3

CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,649

Underlying: Common Stock · 1,331 shares

Expires 2021-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-19-001282 · form4.xml · nonDerivative · entry 2

CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 917

SEC source: 0001127602-19-001282 · form4.xml · nonDerivative · entry 1

CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,331

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-18-035371 · form4.xml · derivative · entry 2

Kramer Robin · CIK 0001609222 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 265

Underlying: Common Stock · 265 shares

Expires 2021-12-03

SEC source: 0001127602-18-035371 · form4.xml · derivative · entry 1

Kramer Robin · CIK 0001609222 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 530

Underlying: Common Stock · 530 shares

Expires 2021-12-03

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-18-035245 · form4.xml · derivative · entry 5

Guindo Chirfi · CIK 0001722753 · EVP Glob. Mkt Acc & Cust Innov

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,342

Underlying: Common Stock · 566 shares

Expires 2020-12-01

F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-18-035245 · form4.xml · derivative · entry 4

Guindo Chirfi · CIK 0001722753 · EVP Glob. Mkt Acc & Cust Innov

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,908

Underlying: Common Stock · 602 shares

Expires 2020-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-18-035245 · form4.xml · nonDerivative · entry 3

Guindo Chirfi · CIK 0001722753 · EVP Glob. Mkt Acc & Cust Innov

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,543

SEC source: 0001127602-18-035245 · form4.xml · nonDerivative · entry 2

Guindo Chirfi · CIK 0001722753 · EVP Glob. Mkt Acc & Cust Innov

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,721

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-18-035245 · form4.xml · nonDerivative · entry 1

Guindo Chirfi · CIK 0001722753 · EVP Glob. Mkt Acc & Cust Innov

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,119

SEC source: 0001127602-18-035013 · form4.xml · nonDerivative · entry 1

SCHENK LYNN · CIK 0001236534 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,877

SEC source: 0001127602-18-032080 · form4.xml · nonDerivative · entry 4

SHERWIN STEPHEN A · CIK 0001079462 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,164

SEC source: 0001127602-18-032080 · form4.xml · nonDerivative · entry 3

SHERWIN STEPHEN A · CIK 0001079462 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,339

SEC source: 0001127602-18-032080 · form4.xml · nonDerivative · entry 2

SHERWIN STEPHEN A · CIK 0001079462 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,539

SEC source: 0001127602-18-032080 · form4.xml · nonDerivative · entry 1

SHERWIN STEPHEN A · CIK 0001079462 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,739

SEC source: 0001127602-18-028453 · form4.xml · nonDerivative · entry 1

Ehlers Michael D · CIK 0001674364 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,281.171

F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

SEC source: 0001127602-18-024587 · form4.xml · derivative · entry 5

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 854

Underlying: Common Stock · 164 shares

Expires 2020-08-01

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

F2 · derivative.underlying_shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

SEC source: 0001127602-18-024587 · form4.xml · derivative · entry 4

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,018

Underlying: Common Stock · 262 shares

Expires 2020-08-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-18-024587 · form4.xml · nonDerivative · entry 3

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 959

SEC source: 0001127602-18-024587 · form4.xml · nonDerivative · entry 2

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,044

SEC source: 0001127602-18-024587 · form4.xml · nonDerivative · entry 1

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,122

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-18-022624 · form4.xml · derivative · entry 1

Karp Daniel · CIK 0001744046 · EVP, Corporate Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,760

Underlying: Common Stock · 1,760 shares

Expires 2021-07-02

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-18-020987 · form4.xml · nonDerivative · entry 1

DENNER ALEXANDER J · CIK 0001361754 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,909

SEC source: 0001127602-18-020970 · form4.xml · nonDerivative · entry 1

Posner Brian S · CIK 0001372455 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,210

SEC source: 0001127602-18-020966 · form4.xml · nonDerivative · entry 1

PANGIA ROBERT W · CIK 0001236188 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,587